Publications by authors named "Thomas Machnig"

Claim this Profile
H
Hypertension risk in patients having hereditary angioedema with plasminogen gene mutation K330E.
Konrad Bork, Karin Wulff, Peter Meinke, Thomas Machnig, Jochen Hardt

J Allergy Clin Immunol Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate.
Marc A Riedl, David R Hinds, Patricia M Prince, Trevor M Alvord, Sara Dosenovic, Thomas Machnig

Allergy Asthma Proc· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
William R Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Thomas Machnig

Orphanet J Rare Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters.
Avner Reshef, Donald Levy, Hilary Longhurst, Marco Cicardi, Timothy Craig, Thomas Machnig

Thromb Haemost· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
William R Lumry, Bruce Zuraw, Marco Cicardi, Timothy Craig, John Anderson, Thomas Machnig

Orphanet J Rare Dis· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence.
Konrad Bork, Thomas Machnig, Karin Wulff, Guenther Witzke, Subhransu Prusty

Orphanet J Rare Dis· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.
Timothy Craig, William Lumry, Marco Cicardi, Bruce Zuraw, Jonathan A Bernstein, Thomas Machnig

J Allergy Clin Immunol Pract· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene.
Konrad Bork, Karin Wulff, Guenther Witzke, Thomas Machnig, Jochen Hardt

Orphanet J Rare Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
William R Lumry, Timothy Craig, Bruce Zuraw, Hilary Longhurst, James Baker, Thomas Machnig

J Allergy Clin Immunol Pract· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study.
H Henry Li, Bruce Zuraw, Hilary J Longhurst, Marco Cicardi, Konrad Bork, Thomas Machnig

Allergy Asthma Clin Immunol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks.
Jonathan A Bernstein, Huamin Henry Li, Timothy J Craig, Michael E Manning, John-Philip Lawo, Thomas Machnig

Allergy Asthma Clin Immunol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.
Marc A Riedl, Aleena Banerji, Michael E Manning, Earl Burrell, Namita Joshi, Thomas Machnig

Orphanet J Rare Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema.
Ying Zhang, Michael A Tortorici, Dipti Pawaskar, Ingo Pragst, Thomas Machnig

CPT Pharmacometrics Syst Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States.
Marc A Riedl, Aleena Banerji, Paula J Busse, Douglas T Johnston, Mark A Davis-Lorton, Thomas Machnig

Ann Allergy Asthma Immunol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema.
Marco Cicardi, Andrea Zanichelli, Chiara Suffritti, Maddalena A Wu, Thomas Machnig

J Allergy Clin Immunol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.
Hilary Longhurst, Marco Cicardi, Timothy Craig, Konrad Bork, Clive Grattan, Thomas Machnig

N Engl J Med· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema.
Timothy Craig, Ralph Shapiro, Arthur Vegh, James W Baker, Jonathan A Bernstein, Thomas Machnig

Allergy Rhinol (Providence)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor.
Henriette Farkas, Lilian Varga, Dumitru Moldovan, Krystyna Obtulowicz, Todor Shirov, Thomas Machnig

Ann Allergy Asthma Immunol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency.
Konrad Bork, Jonathan A Bernstein, Thomas Machnig, Timothy J Craig

J Emerg Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.
Konrad Bork, Timothy J Craig, Jonathan A Bernstein, Henrike Feuersenger, Thomas Machnig

Allergy Asthma Proc· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry.
Paula Busse, Anette Bygum, Jonathan Edelman, William Lumry, Thomas Machnig

J Allergy Clin Immunol Pract· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema.
Annette Feussner, Uwe Kalina, Peter Hofmann, Thomas Machnig, Georg Henkel

Transfusion· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of weight on the efficacy and safety of C1 esterase inhibitor concentrate for the treatment of acute hereditary angioedema.
Jonathan A Bernstein, Thomas Machnig, Heinz-Otto Keinecke, Glenn J Whelan, Timothy J Craig

Clin Ther· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review.
Konrad Bork, Isabella Steffensen, Thomas Machnig

Allergy Asthma Proc· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks.
Timothy J Craig, Mikhail A Rojavin, Thomas Machnig, Heinz-Otto Keinecke, Jonathan A Bernstein

Ann Allergy Asthma Immunol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis